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ABSTRACT
Objective People with type 2 diabetes on insulin are at 
risk for hypoglycemia. Recurrent hypoglycemia can cause 
impaired awareness of hypoglycemia (IAH), and increase 
the risk for severe hypoglycemia. The aim of this study was 
to assess the prevalence and determinants of self- reported 
IAH and severe hypoglycemia in a Dutch nationwide cohort 
of people with insulin- treated type 2 diabetes.
Research design and methods Observational study of 
The Dutch Diabetes Pearl, a cohort of people with type 
2 diabetes treated in primary, secondary and tertiary 
diabetes care centers. The presence of IAH and the 
occurrence of severe hypoglycemia in the past year, 
defined as an event requiring external help to recover, 
were assessed using the validated Dutch version of the 
Clarke questionnaire. In addition, clinical variables were 
collected including age, diabetes duration, hemoglobin 
A1c, ethnicity and education.
Results 2350 people with type 2 diabetes on insulin 
were included: 59.1% men, mean age 61.1±10.4 years, 
mean diabetes duration 14.8±9.2 years and 79.5% 
on basal- bolus therapy. A total of 229 patients (9.7%) 
were classified as having IAH and 742 patients (31.6%) 
reported severe hypoglycemia. Increased odds for IAH 
were found with complex insulin regimens and lower 
odds with having a partner and body mass index ≥30 kg/
m2. Severe hypoglycemia was associated with complex 
insulin regimens, non- Caucasian ethnicity and use of 
psychoactive drugs, and inversely with metformin use.
Conclusions In this nationwide cohort, almost one out 
of ten people with type 2 diabetes on insulin had IAH and 
>30% had a history of severe hypoglycemia in the past 
year.
InTROduCTIOn
Insulin- related hypoglycemia is a common 
adverse effect of insulin therapy. Recent data 
show almost 98 000 visits to the emergency 
department and 30 000 hospitalizations in the 
USA per year due to insulin- related hypogly-
cemia.1 Over 75% of these emergency depart-
ment visits occur in middle- aged or elderly 
people, suggesting that most of these people 
suffer from type 2 diabetes.
The reported prevalence of hypoglycemic 
events in people with type 2 diabetes on 
insulin therapy is highly variable and partly 
determined by the duration and intensity of 
Significance of this study
What is already known about this subject?
 ► Use of insulin therapy in patients with type 2 diabetes 
creates a risk of developing (severe) hypoglycemia.
 ► Recurrent (severe) hypoglycemia may lead to the 
development of impaired awareness of hypoglyce-
mia (IAH).
 ► The prevalence of IAH in patients with type 1 dia-
betes is around 25%; however, less is known about 
the prevalence of IAH in people with type 2 diabetes.
What are the new findings?
 ► In this nationwide cohort, the prevalence of IAH in 
patients with type 2 diabetes on insulin therapy was 
almost 10%.
 ► The prevalence of severe hypoglycemia in this co-
hort was more than 30%.
 ► IAH and severe hypoglycemia occur in patients ir-
respective of whether they are managed in primary 
care or not.
How might these results change the focus of 
research or clinical practice?
 ► Greater awareness for IAH and severe hypoglycemia 
in people with type 2 diabetes on insulin is needed.
 ► Appropriate education to reduce the risk of hypogly-
cemia in these patients seems warranted
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Figure 1 Flow diagram showing patient selection.
insulin therapy. Previous studies have shown that people 
with type 2 diabetes treated with insulin for <2 years expe-
rience on average four non- severe episodes per person- 
year, whereas those treated for >5 years experience 10 
episodes per person- year.2 3 Similarly, severe hypogly-
cemia, defined as an event requiring external help to 
recover, rarely occurs in the first years after the start of 
insulin therapy but becomes more common during later 
years.4 5 One report estimated the overall prevalence 
of severe hypoglycemia in type 2 diabetes treated with 
insulin in secondary care at 0.28 episodes per patient per 
year.6
Recurrent exposure to hypoglycemia can induce a 
process of habituation leading to impaired awareness 
of hypoglycemia (IAH). This syndrome increases the 
risk for developing severe hypoglycemia considerably,5 6 
yet reflects a functional defect that can be reversed by 
strict avoidance of hypoglycemia.7–9 IAH has been well 
described in type 1 diabetes and affects approximately 
25% of people with type 1 diabetes, a percentage that 
appears relatively stable across different cohorts and over 
time.10–12 Less information is available concerning the 
prevalence of IAH in type 2 diabetes, with reported prev-
alence of IAH in single- centre surveys varying between 
7% and 46% among those treated with insulin.5 6 13–15 
The aim of this study was to assess the prevalence and 
determinants of IAH and severe hypoglycemia in a large 
nationwide cohort of patients with insulin- treated type 2 
diabetes.
ReseaRCH desIgn and MeTHOds
study design
The Dutch Diabetes Pearl is an observational cohort study 
of people with type 2 diabetes in the Netherlands. The 
participants are managed in primary care (in the Hoorn 
area or the region of Maastricht) or in secondary and 
tertiary care in seven of the total eight academic medical 
centers across the country. Details on the design of the 
Dutch Diabetes Pearl have been published previously.16 
The study was approved by Institutional Review Boards 
of all the participating medical centers. Patients were 
excluded if they were unable to understand and write the 
Dutch language.
study population
Patients were enrolled in the Dutch Diabetes Pearl 
cohort between 2009 and 2015.16 For this analysis, we 
only included patients with type 2 diabetes who were 
treated with insulin. We excluded patients that did not 
fill in the Clarke questionnaire, including all participants 
from one center that did not administer this question-
naire (figure 1).
study procedure
After signing informed consent, data were collected 
following standard operational procedures. Briefly, we 
collected the following data in the Diabetes Pearl: demo-
graphics, physical examinations, laboratory measure-
ments and several questionnaires including the validated 
Dutch version of the Clarke questionnaire (see below for 
details).16
study outcomes
The primary outcome of this study was the prevalence of 
IAH in people with type 2 diabetes on insulin therapy. 
All participants were therefore asked to complete the 
clamp- validated Dutch modified translation of the Clarke 
questionnaire.17 18 This questionnaire consists of a vali-
dated translation of the original five questions; two ques-
tions on symptoms of hypoglycemia, one on the ability to 
recognize hypoglycemia based on symptoms, one on the 
level of blood glucose when experiencing hypoglycemic 
symptoms, and two questions on the occurrence of severe 
hypoglycemia, one relating to the requirement of a third 
party, one relating to the need for medical assistance, 
both in the past year. Each question was awarded with 
one or zero points, with three or more out of five points 
indicating IAH. Severe hypoglycemia was defined by a 
positive answer to one of both questions regarding severe 
hypoglycemia. Missing data on the Clarke questionnaire 
were imputed with 0 (having no symptoms) if patients 
filled in at least one answer.
Other measurements
We also assessed a range of demographic and clinical 
factors including age, diabetes duration, hemoglobin 
A1c (HbA1c), ethnicity, smoking, alcohol consumption, 
having a partner and level of education, to identify poten-
tial risk factors, as described below.
Hospital information systems at all recruitment centers 
were used to collect information on date of birth and 
gender. Ethnicity was estimated as described earlier.19 
Education level was self- reported. A high educational 
level was defined as higher professional education or 
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university education. Information on alcohol consump-
tion and smoking were obtained by questionnaire; 
smoking was categorized as never, former and current 
smoking. Body mass index (BMI) was defined as a 
person’s weight (kilograms) divided by square of height 
(meters). Participants brought all their medication or 
a list from the pharmacy to the hospital so that medi-
cation use (eg, beta- blockers and psychoactive drugs) 
could be reported accurately. Drug use was divided into 
three arbitrary categories; no polypharmacy (0–4 drugs), 
moderate polypharmacy (5–9 drugs) and pronounced 
polypharmacy (≥10 drugs). The insulin regimen was 
categorized as basal only if it consisted of a long- acting 
insulin analogue or intermediate- acting insulin (ie, 
NPH (Neutral Protamine Hagedorn) insulin) alone, 
as pre- mixed if it consisted of pre- mixed insulins, and 
as basal- bolus (complex insulin regimen) if it consisted 
of a combination of long- acting or intermediate- acting 
insulin with short- acting insulin. The latter two regimens 
were considered ‘complex’ for the logistic regression 
analysis (see below). History of cardiovascular disease 
was defined as at least one of the following events having 
occurred: acute myocardial infarction, cerebrovascular 
event, transient ischemic attack and peripheral artery 
disease. Information on prior cardiovascular disease was 
assessed by the Rose questionnaire.20 HbA1c was reported 
according to the International Federation of Clinical 
Chemistry and Laboratory Medicine standard.21 Tight 
glycemic control was defined as HbA1c <7% (53 mmol/
mol). All measurements took place in certified on- site 
laboratories.16
statistical analysis
Data were analyzed using IBM SPSS statistics V.25. Base-
line descriptive analyses were expressed as mean±SD, 
proportion or median (25th and 75th percentiles). 
Student’s independent two- sample t- tests and Pearson’s 
χ2 tests were performed to examine differences between 
groups. We performed logistic regression analyses to 
examine the association between several demographic 
and clinical variables and IAH and severe hypoglycemia. 
The regression model for IAH and severe hypoglycemia 
were cumulatively adjusted for age, sex, diabetes dura-
tion, HbA1c, and for other variables that were significantly 
associated with the outcome in the crude analysis. A p 
value of <0.05 was considered statistically significant.
ResulTs
The Diabetes Pearl cohort consists of 7018 individuals.16 
After excluding participants who were not using insulin 
(n=4303) did not complete the Clarke questionnaire 
(n=226) or had too many missing data on the question-
naire (n=139), we included a total of 2350 patients with 
type 2 diabetes (figure 1). There were 59.1% male partic-
ipants, mean age was 61.1±10.4 years, mean diabetes 
duration 14.8±9.2 years and mean HbA1c 7.9%±1.4% 
(62.5±14.8 mmol/mol). Almost 80% were on a complex 
insulin regimen (online supplementary table S1).
Impaired awareness of hypoglycemia
The distribution of the modified Clarke score was highly 
skewed (online supplementary figure S1), with a total of 
229 individuals (9.7%) having a score of ≥3 points, classi-
fying them as having IAH. Clinical characteristics of the 
individuals with and without IAH are shown in table 1. 
There were no significant differences in the prevalence 
of IAH between men and women (10.2 vs 9.1%, p=NS) 
and between patients managed in primary or secondary/
tertiary care (8.2 vs 10.4%, p=NS). Although glycemic 
control did not differ between individuals with or without 
IAH, the prevalence of IAH was significantly higher among 
individuals with tight glycemic control as compared with 
those with glycemic control that was less tight (p=0.046) 
(figure 2, top). The presence of IAH was associated with 
complex insulin regimens, non- Caucasian ethnicity, lower 
BMI and not having a partner, and inversely with the use 
of sulfonylureas. After multivariate adjustment, complex 
insulin regimens, not having a partner and lower BMI 
were still associated with IAH (table 2). There were no 
statistical differences between the two groups concerning 
smoking, alcohol consumption, diabetes duration and 
use of beta- blockers or psychoactive drugs.
severe hypoglycemia
Severe hypoglycemia in the past 12 months was reported 
by 742 patients (31.6%), 193 (8.2%) of whom required 
medical intervention. The prevalence of severe hypo-
glycemia was similar across sex, but significantly higher 
among those with poorer glycemic control (p=0.016) 
(figure 2, bottom). People with a history of severe hypo-
glycemia were more often non- Caucasian, had a longer 
diabetes duration, had a history of cardiovascular events, 
used psychoactive drugs and reported pronounced 
polypharmacy (table 1). Furthermore, people with 
severe hypoglycemia were more likely to use complex 
insulin regimens and less likely to use sulfonylureas or 
metformin, and were more often seen in secondary/
tertiary care than in primary care centers when compared 
with people without severe hypoglycemia. However, after 
multivariate adjustment, the level of care was no longer 
associated with severe hypoglycemia and the same was 
true for use of sulfonylureas, pronounced polypharmacy 
and history of cardiovascular disease (table 3).
COnClusIOns
In this nationwide cohort of patients with type 2 diabetes 
treated with insulin, we found that the prevalence of IAH 
was 9.7% and that almost one out of three individuals 
reportedly experienced a severe hypoglycemic event in 
the preceding year. We observed that people not having 
a partner, with more complex insulin treatment regi-
mens, use of psychoactive drugs, BMI <30 kg/m2 and 
non- Caucasian descent were more susceptible for IAH or 
severe hypoglycemia. Interestingly, tight glycemic control 
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Table 1 Clinical characteristics of people (n=2350) with or without IAH and severe hypoglycemia
Characteristic IAH (n=229) No IAH (n=2121)
Severe hypoglycemia 
(n=742)
No severe 
hypoglycemia (n=1608)
Sex (male) 142 (62.0) 1248 (58.8) 437 (58.9) 953 (59.3)
Age (years) 59.9±11.0 61.2±10.3 60.8±10.5 61.2±10.3
Clinical care
  Primary care 55 (24.0) 614 (28.9) 185 (25.1)* 484 (30.2)
  Secondary/tertiary 
care
173 (75.5) 1497 (70.6) 551 (74.9)* 1119 (69.8)
Diabetes duration 
(years)
15.5±9.7 14.7±9.1 15.7±9.4* 14.3±9.0
HbA1c (%) (mmol/mol) 7.8±1.4 (61.4±15.3) 7.9±1.3 (62.6±14.7) 8.0±1.4 (63.7±15.5) 7.8±1.3 (62.0±14.4)
Insulin treatment
  Basal only 25 (10.9)† 453 (21.4) 106 (14.3)* 372 (23.1)
  Pre- mixed 40 (17.5) 339 (16.0) 122 (16.4) 257 (16.0)
  Basal- bolus 163 (71.2)† 1327 (62.6) 513 (69.1)* 977 (60.8)
Use of sulfonylureas 12 (5.2)† 240 (11.3) 59 (8.0)* 193 (12.0)
Use of metformin 128 (55.9) 1324 (62.4) 423 (57.0)* 1029 (64.0)
Pronounced 
polypharmacy
73 (31.9) 632 (29.8) 263 (35.4)* 442 (27.5)
Beta- blocker use 86 (37.6) 859 (40.5) 298 (40.2) 647 (40.2)
Psychoactive drug 
use
52 (22.7) 477 (22.5) 209 (28.2)* 320 (19.9)
Ethnicity (Caucasian) 169 (75.4)† 1714 (81.5) 565 (77.2)* 1318 (82.6)
Partner (yes) 122 (63.2)† 1301 (73.5) 443 (72.0) 980 (72.7)
High educational 
level (yes)
54 (23.8) 499 (23.6) 159 (21.6) 394 (24.6)
Current smoker (yes) 47 (20.6) 389 (18.4) 145 (19.6) 291 (18.2)
High alcohol 
consumption (≥14 
glasses/week)
15 (6.6) 132 (6.3) 49 (6.7) 98 (6.2)
BMI≥30 (kg/m2) 112 (49.3)† 1198 (57.3) 410 (55.8) 900 (56.9)
History of 
cardiovascular 
disease (yes)
81 (35.4) 645 (30.4) 261 (35.2)* 465 (28.9)
Data are shown as number (%) or mean±SD. History of cardiovascular disease was defined as having ≥1 of the following; acute myocardial 
infarction, cerebrovascular event, transient ischemic attack, peripheral artery disease. Pronounced polypharmacy was defined as using ≥10 
drugs.
*p<0.05 versus no SH.
†p<0.05 versus no IAH
BMI, body mass index; IAH, impaired awareness of hypoglycemia; SH, severe hypoglycemia.
was associated with a higher prevalence of IAH, but at 
the same time with a lower risk of severe hypoglycemia. 
Furthermore, the prevalence of severe hypoglycemia 
was significantly higher in secondary/tertiary care, but 
the association between level of care and severe hypogly-
cemia was no longer statistically significant after multivar-
iate adjustment.
Our data on the prevalence of IAH in people with 
insulin- treated type 2 diabetes are in line with those 
reported in small studies using either the Gold score6 13 
or the Clarke questionnaire,22 and extend these to a more 
general population of people with type 2 diabetes on 
insulin, including those from primary care. In accor-
dance with previous findings, participants with IAH had 
somewhat tighter and those with severe hypoglycemia 
had somewhat poorer metabolic control.13 23 24 Our data 
contrast with single- center surveys from Denmark5 14 and 
Turkey25 that reported IAH to vary between 31% and even 
94% among people with type 2 diabetes on insulin. Part 
of this discrepancy may result from differences between 
questionnaires, thus potentially identifying different 
subgroups. We used the Dutch modified version of the 
Clarke questionnaire, which has been validated against 
hypoglycemic clamps in people with type 1 diabetes.17 
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Figure 2 Proportion (%) of patients with IAH (top) or severe 
hypoglycemia (SH) (bottom) according to glycemic category, 
7%=53 mmol/mol, 8%=64 mmol/mol, *P value for trend 
<0.05. IAH, impaired awareness of hypoglycemia.
Table 2 Logistic regression analyses to assess the association between variables and IAH in people with type 2 diabetes on 
insulin
Variable
OR (95% CI)
Crude analysis
OR (95% CI)
Model 1
OR (95% CI)
Model 2
OR (95% CI)
Model 3
Caucasian ethnicity 0.70 (0.51–0.97) 0.73 (0.52–1.02) 0.69 (0.48–0.99) 0.76 (0.52–1.12)
Having a partner 0.62 (0.45–0.85) 0.60 (0.44–0.82) 0.59 (0.42–0.82) 0.59 (0.42–0.84)
BMI≥30 kg/m2 0.73 (0.55–0.95) 0.72 (0.55–0.95) 0.78 (0.58–1.06) 0.71 (0.51–0.98)
Complex insulin regimen 2.21 (1.44–3.39) 2.20 (1.43–3.38) 2.01 (1.29–3.16) 1.75 (1.06–2.88)
Use of sulfonylureas 0.43 (0.24–0.79) 0.44 (0.24–0.81) 0.47 (0.25–0.88) 0.62 (0.30–1.26)
Statistically significant data (p<0.05) appear in boldface type. Model 1 is adjusted for age and sex. Model 2 is adjusted for age, sex, HbA1c 
and diabetes duration. Model 3 is adjusted for age, sex, HbA1c and diabetes duration and for all other variables mentioned in table 2. 
Complex insulin regimen: a regimen consisting of pre- mixed insulin or combination of short- acting and intermediate- acting or long- acting 
insulin.
BMI, body mass index ; IAH, impaired awareness of hypoglycemia.
The methods by Gold and Clarke have a good mutual 
concordance and good predictability for biochemical 
hypoglycemia, but correlate less well with the method 
used in Denmark.26 The latter method has been criti-
cized for overestimating the prevalence of IAH.26 27
IAH was almost as prevalent in people with type 2 
diabetes managed by primary care physicians as in those 
managed in secondary/tertiary care centers. The prev-
alence of severe hypoglycemia was slightly higher in 
secondary/tertiary care when compared with primary 
care. In fact, the association between type of care and 
severe hypoglycemia was completely lost after correction 
for age, sex, diabetes duration and HbA1c. Conversely, use 
of a complex insulin regimen increased the risk for both 
IAH and severe hypoglycemia, which was independent 
of where they received their care. The size and diversity 
of our cohort enabled us to also uncover non- Caucasian 
ethnicity and having no partner as independent new 
determinants of severe hypoglycemia and IAH, respec-
tively, in people with type 2 diabetes, whereas we found 
no evidence for associations with smoking, as reported 
previously.23
Use of metformin was independently associated with 
lower odds of severe hypoglycemia in our population, 
which corroborates findings of a recent large cohort 
study.28 The underlying mechanism explaining this 
observation remains to be determined. Metformin has 
been shown to modestly enhance the release of growth 
hormone during hypoglycemia, but not that of other 
counterregulatory hormones.29 Alternatively, metformin- 
induced increases in plasma lactate may preserve brain 
function during hypoglycemia, thus potentially providing 
protection against severe hypoglycemia.30 31 In univariate 
analysis, we also found an inverse relationship between 
use of sulfonylureas and IAH or severe hypoglycemia. 
Since particularly long- acting sulfonylureas are associ-
ated with increased risks of hypoglycemia,32 33 this seem-
ingly paradoxical finding is best explained by reverse 
causality. Indeed, it is highly likely that sulfonylureas were 
stopped after intensifying insulin therapy, in accordance 
with international guidelines,34 or after experiencing 
severe or frequent hypoglycemic events, and not even 
commenced in patients thought to be at increased risk 
of hypoglycemia.
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Table 3 Logistic regression analyses to assess the association between variables and severe hypoglycemia in people with 
type 2 diabetes on insulin
Variable
OR (95% CI)
Crude analysis
OR (95% CI)
Model 1
OR (95% CI)
Model 2
OR (95% CI)
Model 3
Caucasian ethnicity 0.72 (0.58–0.89) 0.72 (0.58–0.90) 0.75 (0.60–0.96) 0.69 (0.54–0.88)
Clinical care (secondary/tertiary) 1.29 (1.06–1.57) 1.28 (1.05–1.56) 1.16 (0.93–1.44) 0.92 (0.72–1.16)
Complex insulin regimen 1.81 (1.43–2.29) 1.80 (1.42–2.28) 1.64 (1.27–2.12) 1.44 (1.07–1.94)
Use of sulfonylureas 0.63 (0.47–0.86) 0.64 (0.47–0.87) 0.68 (0.50–0.95) 0.88 (0.60–1.27)
Use of metformin 0.75 (0.63–0.89) 0.74 (0.62–0.88) 0.75 (0.62–0.91) 0.76 (0.62–0.93)
Pronounced polypharmacy 1.45 (1.20–1.75) 1.48 (1.22–1.78) 1.40 (1.15–1.71) 1.22 (0.97–1.54)
Use of psychoactive drugs 1.58 (1.29–1.93) 1.58 (1.29–1.94) 1.54 (1.24–1.91) 1.37 (1.08–1.75)
History of cardiovascular disease 1.33 (1.11–1.61) 1.37 (1.13–1.65) 1.26 (1.03–1.54) 1.17 (0.95–1.45)
Statistically significant data (p<0.05) appear in boldface type. Model 1 is adjusted for age and sex. Model 2 is adjusted for age, sex, HbA1c 
and diabetes duration. Model 3 is adjusted for age, sex, HbA1c, diabetes duration and diabetes duration and for all other variables mentioned 
in table 2. Complex insulin regimen: a regimen consisting of pre- mixed insulin or combination of short- acting and intermediate- or long- 
acting insulin.
Our study has clinical implications as it shows that both 
IAH and severe hypoglycemia are common in people 
with type 2 diabetes on insulin therapy, even in those 
using basal insulin therapy alone or managed in primary 
care. Remarkably, although the prevalence of IAH in type 
2 diabetes is at least twofold lower than what has been 
reported in type 1 diabetes, the occurrence of severe 
hypoglycemia was at least of the same magnitude.10 11 35 36 
A lack in education about hypoglycemia focused on this 
population may explain at least a part of this discrep-
ancy. The symptomatology of hypoglycemia may differ in 
elderly people with type 2 diabetes, whereas those with 
type 1 diabetes are usually younger, have longer expe-
rience with insulin treatment and consequently may 
already have been educated more intensively and more 
frequently about hypoglycemia.37 38 Some other risk 
factors for IAH in our study, for example non- Caucasian 
ethnicity, may also be partly explained by an educational 
gap. Focused education may reduce the burden of hypo-
glycemia and its potentially harmful consequences (eg, 
falls), as well as the associated risk of cardiovascular 
morbidity and mortality.39–41
Strengths of our study include the size of the cohort, 
being the largest to date in which the prevalence of IAH 
in type 2 diabetes has been determined and its national 
coverage due to the collaboration of all academic 
medical centers in the Netherlands. The inclusion of 
primary, secondary and tertiary care patients and the use 
of standardized protocols for data collection increase 
its generalizability. Our study also has limitations. Based 
on selection by academic centers, there may be an over- 
representation of complicated tertiary care patients. 
However, it should be noted that most previous studies 
also collected data in academic centers.6 13 22 Second, the 
questionnaire we used to estimate IAH has not formally 
been validated in type 2 diabetes, but this applies to all 
questionnaires currently used for this purpose. Future 
research is needed to validate the questionnaire in 
patients with type 2 diabetes. Finally, we did not measure 
C- peptide values, the presence of which has been associ-
ated with lower hypoglycemia risks in people with type 1 
diabetes,42 and most data were collected before the wide-
spread use of continuous glucose monitoring techniques.
In conclusion, IAH and severe hypoglycemia are rela-
tively common among people with type 2 diabetes treated 
with insulin, particularly when managed with an intensi-
fied regimen, but independent of whether this is applied 
in primary, secondary or tertiary care. Greater awareness 
for IAH and severe hypoglycemia in people with type 2 
diabetes on insulin is needed, with special attention for 
people without a partner or with non- Caucasian ethnic-
ities. Appropriate education to reduce the risk of hypo-
glycemia in people with type 2 diabetes on insulin seems 
warranted, although this remains to be investigated.
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